Kailera and Hengrui Present Promising Ribupatide Data at ADA 2026, Demonstrating Strong Weight Loss Efficacy
Key Insights
Hengrui's Phase 2 trial of oral ribupatide (search) showed participants achieved mean weight loss up to 12.1% with no plateau at Week 26, with 38.6% achieving at least 15% weight loss.
Kailera presented Phase 1 bridging study data for ribupatide (search) injection at ADA 2026, supporting their ongoing global Phase 3 KaiNETIC clinical program.
The companies are advancing multiple formulations of ribupatide (search), a GLP-1 (search)/GIP (search) receptor dual agonist, including oral and injectable versions for obesity (search) treatment.
Kailera Therapeutics (search) and Hengrui Pharma presented compelling clinical data for ribupatide (search), a GLP-1 (search)/GIP (search) receptor dual agonist, at the American Diabetes Association's 86th Scientific Sessions in June 2026, showcasing the therapeutic potential of both oral and injectable formulations for obesity (search) treatment.
Phase 2 Oral Ribupatide Demonstrates Significant Weight Loss
Hengrui's Phase 2 clinical trial of oral ribupatide (search) (HRS9531) in adults with obesity (search) delivered notable efficacy results. Participants achieved a mean weight loss of up to 12.1% with no observed plateau at Week 26, indicating potential for continued weight reduction. Particularly striking was the finding that up to 38.6% of participants taking oral ribupatide achieved at least 15% weight loss, a threshold considered clinically meaningful for obesity treatment.
The trial also demonstrated a potentially highly differentiated tolerability profile, with low rates of gastrointestinal adverse events observed compared to typical GLP-1 (search)-based therapies. This favorable safety profile could represent a significant advantage in the competitive obesity (search) treatment landscape.
Injectable Formulation Advances Through Phase 1 Studies
Kailera presented data from their Phase 1 bridging study of ribupatide (search) injection (KAI-9531), which provided the foundation for initiating their ongoing global Phase 3 KaiNETIC clinical program. The company has since launched a U.S. Phase 2b high-dose obesity (search) clinical trial designed to evaluate whether higher doses can achieve even greater weight loss.
This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 250 participants with a BMI of 35 or greater and no type 2 diabetes (search). Participants will receive either placebo or doses up to 20 mg of ribupatide (search) injection administered over 48 weeks, with data anticipated in 2027.
Expanding Clinical Pipeline
Beyond ribupatide (search), the companies are advancing additional obesity (search) treatments. Kailera initiated a global Phase 2 obesity trial for KAI-7535, a once-daily oral small molecule GLP-1 (search) receptor agonist. The double-blind, randomized, placebo-controlled trial will enroll approximately 320 participants with a BMI of 30+ or a BMI of 27+ with at least one co-morbidity, including potential type 2 diabetes (search) patients.
Hengrui also reported positive results from OUTSTAND-1, their Phase 3 type 2 diabetes (search) clinical trial of HRS-7535 (KAI-7535). The trial met its primary endpoint at Week 32, demonstrating significant HbA1c reductions across all three dose levels (30 mg, 60 mg, and 90 mg) compared to placebo. Based on the efficacy estimand, HbA1c reductions ranged from 1.40% to 1.68%, compared to 0.06% for placebo.
Triple Agonist Shows Promise
The companies also reported positive topline data from Hengrui's Phase 1 trial of HRS-4729 (KAI-4729), a once-weekly injectable GLP-1 (search)/GIP (search)/glucagon receptor (search) tri-agonist. In the multiple ascending dose portion of the trial, participants receiving 12 mg of HRS-4729 achieved a mean weight loss of up to 16.0% from baseline at Week 12, compared to 5.4% with placebo.
HRS-4729 demonstrated linear pharmacokinetics with a half-life of approximately 4 to 5 days, supporting once-weekly dosing. The compound also showed dose-dependent reduction in liver fat content as measured by magnetic resonance imaging, suggesting potential benefits for metabolic dysfunction-associated steatohepatitis (search) (MASH).
Strategic Positioning
Kailera's obesity (search)-first focus distinguishes the company in a crowded field of metabolic disease treatments. The company's diversified pipeline leverages multiple GLP-1 (search)-based mechanisms of action and routes of administration, designed to address critical needs in the current therapeutic landscape.
The company recently completed an initial public offering, raising $718.8 million in gross proceeds and began trading on the Nasdaq Global Select Market under the ticker symbol "KLRA" in April 2026. This funding supports the advancement of their clinical programs, with multiple data readouts expected in 2027.